Bell2Bell Podcast featuring Annovis Bio Inc. (NYSE: ANVS) CEO Dr. Maria Maccecchini
The Bell2Bell (B2B) Podcast · 2024-08-05 · 9 min
Episode notes
IBN , a multifaceted communications organization engaged in connecting public companies to the investment community, is excited to announce the release of the latest episode of The Bell2Bell Podcast , recorded live from the Alzheimer’s Association International Conference® 2024 (AAIC®) in Philadelphia. This release is part of IBN’s ongoing efforts to provide specialized content distribution via widespread syndication channels. The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bell2Bell’s latest podcast features Dr. Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio Inc. (NYSE: ANVS) , a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). Broadcasting live from AAIC 2024, Dr. Maccecchini delves into the detailed findings from Annovis Bio’s recent Phase 2/3 Alzheimer’s study of its lead drug candidate, buntanetap.